Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma.
| Title: | Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma. |
|---|---|
| Authors: | Verkerke H; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Saeedi BJ; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Boyer D; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Allen JW; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Owens J; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Shin S; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Horwath M; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Patel K; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Paul A; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Wu SC; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Wang J; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Ho A; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Maier CL; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Zerra PE; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Chonat S; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Arthur CM; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Roback JD; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Neish AS; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Lough C; LifeSouth Community Blood Centers, Gainesville, Florida, USA.; Josephson CD; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Stowell SR; Center for Transfusion Medicine and Cellular Therapies, Emory University, Atlanta, Georgia, USA.; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. |
| Source: | Transfusion [Transfusion] 2021 Jun; Vol. 61 (6), pp. 1740-1748. Date of Electronic Publication: 2021 May 26. |
| Publication Type: | Case Reports; Journal Article |
| Language: | English |
| Journal Info: | Publisher: American Association Of Blood Banks Country of Publication: United States NLM ID: 0417360 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-2995 (Electronic) Linking ISSN: 00411132 NLM ISO Abbreviation: Transfusion Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Arlington, Va. : American Association Of Blood Banks |
| MeSH Terms: | Convalescence*; COVID-19/*immunology ; COVID-19/*therapy ; Immunoglobulin A/*blood ; SARS-CoV-2/*immunology; Antibodies, Viral/blood ; Down Syndrome/complications ; Down Syndrome/immunology ; Down Syndrome/therapy ; Heart Septal Defects/complications ; Heart Septal Defects/immunology ; Heart Septal Defects/therapy ; Immunity, Humoral/immunology ; Immunization, Passive/methods ; Immunoglobulin A/analysis ; Immunoglobulin G/blood ; Immunoglobulin M/blood ; Blood Donors ; Female ; Humans ; Infant ; Retrospective Studies ; Serologic Tests ; United States ; COVID-19 Serotherapy |
| Abstract: | Background: While convalescent plasma (CP) may benefit patients with COVID-19, fundamental questions remain regarding its efficacy, including the components of CP that may contribute to its therapeutic effect. Most current serological evaluation of CP relies on examination of total immunoglobulin or IgG-specific anti-SARS-CoV-2 antibody levels. However, IgA antibodies, which also circulate and are secreted along the respiratory mucosa, represent a relatively uncharacterized component of CP.; Study Design and Methods: Residual samples from patients and CP donors were assessed for IgM, IgG, and IgA anti-SARS-CoV-2 antibody titers against the receptor-binding domain responsible for viral entry. Symptom onset was obtained by chart review.; Results: Increased IgA anti-SARS-CoV-2 antibody levels correlated with clinical improvement and viral clearance in an infant with COVID-19, prompting a broader examination of IgA levels among CP donors and hospitalized patients. Significant heterogeneity in IgA levels was observed among CP donors, which correlated weakly with IgG levels or the results of a commonly employed serological test. Unlike IgG and IgM, IgA levels were also more likely to be variable in hospitalized patients and this variability persisted in some patients >14 days following symptom onset. IgA levels were also less likely to be sustained than IgG levels following subsequent CP donation.; Conclusions: IgA levels can be very heterogenous among CP donors and hospitalized patients and do not necessarily correlate with commonly employed testing platforms. Examining isotype levels in CP and COVID-19 patients may allow for a tailored approach when seeking to fill specific gaps in humoral immunity.; (© 2021 AABB.) |
| References: | J Clin Microbiol. 2021 Mar 19;59(4):. (PMID: 33468605); Cell Mol Life Sci. 2019 Mar;76(6):1041-1055. (PMID: 30498997); Transfusion. 2021 Apr;61(4):1047-1052. (PMID: 33368395); Lancet. 2020 Jun 6;395(10239):1758-1759. (PMID: 32464112); Adv Immunol. 1992;51:1-84. (PMID: 1502974); Transfus Med Rev. 2020 Apr;34(2):75-80. (PMID: 32107119); Transfusion. 2021 Jun;61(6):1740-1748. (PMID: 34041759); Chest. 2020 Jul;158(1):e9-e13. (PMID: 32243945); N Engl J Med. 2021 Feb 18;384(7):666-668. (PMID: 33440086); Anesthesiology. 2001 Aug;95(2):299-306. (PMID: 11506098); DNA Cell Biol. 2014 Dec;33(12):823-9. (PMID: 25188736); Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264); MAbs. 2019 Aug/Sep;11(6):1122-1138. (PMID: 31122132); Blood Adv. 2020 Sep 22;4(18):4278-4281. (PMID: 32915971); Haematologica. 2020 Mar;105(3):539-544. (PMID: 32029505); N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530); Cell Rep Med. 2020 Jun 23;1(3):100040. (PMID: 32835303); J Clin Invest. 2020 Jun 1;130(6):2757-2765. (PMID: 32254064); J Clin Invest. 2020 Sep 1;130(9):4791-4797. (PMID: 32525844); Haematologica. 2018 Oct;103(10):e483-e485. (PMID: 29794144); Blood. 2012 Jul 19;120(3):528-37. (PMID: 22563085); Transfus Clin Biol. 2019 May;26(2):130-134. (PMID: 30979566); Haematologica. 2020 Jul 30;105(12):2887-2891. (PMID: 33256394); Pediatrics. 2017 Jul;140(1):. (PMID: 28759404); JAMA. 2020 Apr 28;323(16):1582-1589. (PMID: 32219428); Am J Hematol. 2017 Dec;92(12):1340-1348. (PMID: 28924974); Arthritis Rheumatol. 2015 Jul;67(7):1766-77. (PMID: 25833812); J Immunol. 2013 Mar 1;190(5):2362-71. (PMID: 23359507); Clin Infect Dis. 2020 Nov 5;71(8):1935-1936. (PMID: 32357206); Thromb Res. 2020 Jul;191:145-147. (PMID: 32291094); J Immunol. 2004 Aug 1;173(3):1978-86. (PMID: 15265932); J Infect Dis. 2020 Oct 13;222(10):1620-1628. (PMID: 32779705); Anesthesiology. 2003 Mar;98(3):628-32. (PMID: 12606905); Front Immunol. 2013 Jul 12;4:185. (PMID: 23874333); Transfusion. 2021 Apr;61(4):1029-1034. (PMID: 33231313); N Engl J Med. 2021 Feb 18;384(7):610-618. (PMID: 33406353) |
| Grant Information: | T32 GM008169 United States GM NIGMS NIH HHS; T32 HL066987 United States HL NHLBI NIH HHS |
| Contributed Indexing: | Keywords: COVID-19; IgA; antibody isotype; convalescent plasma; serology |
| Substance Nomenclature: | 0 (Antibodies, Viral); 0 (Immunoglobulin A); 0 (Immunoglobulin G); 0 (Immunoglobulin M) |
| SCR Disease Name: | Atrioventricular Septal Defect |
| Entry Date(s): | Date Created: 20210527 Date Completed: 20210630 Latest Revision: 20230727 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC8242454 |
| DOI: | 10.1111/trf.16435 |
| PMID: | 34041759 |
| Database: | MEDLINE |
Case Reports; Journal Article